Summit (Oxford) Limited
Summit Corporation is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical needs. Its first area of focus is Duchenne Muscular Dystrophy (DMD), a fatal genetic muscle wasting disease for which there is currently no cure. DMD has an incidence of 1 in 3,500 and the patient population in the developed world is estimated to be 50,000. Summit’s programme is a potential disease-modifying approach that is expected to treat all DMD patients, regardless of the genetic fault causing their disease. Its second area of focus is Clostridium difficile infection (CDI), a potentially fatal illness that is a major healthcare issue in hospitals and long-term care homes, and increasingly in the wider community. It is estimated that there are currently 900,000 cases across Europe and North America per annum. The rise means CDI has a high economic burden with the annual cost of care in Europe and North America estimated to be in excess of $7 billion.